Echtzeitaktualisierungen für Harbin Pharmaceutical [600664.SS]

Harbin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacture, and trade of pharmaceuticals in China and internationally. The company operates through seven segments: Antibiotics, Small-Molecular Drug Preparations, OTC and Healthcare Products, Modern Chinese Medicines, Biopharmaceuticals, Animal Vaccines, and Medicine Circulations. It offers a series of penicillin and cephalosporin products, as well as intermediates. The company's lead products include Shuang Huanglian freeze-dried injection; Danshen freeze-dried injection; Shuang Huanglian powder for injection; roxithromycin dispersible tablets; belladonna, sulfamethoxazole, and trimerhoprim tablets; pediatric paracetamol, atificial cow-bezoar, and chlorphenamine maleate granules; Shuanghuanglian oral liquid; and ceftriaxone sodium for injection. Its lead products also comprise amoxicillin capsules, cefotiam hydrochloride for injection, panax ginseng extract, cefepime hydrochloride for injection, cefoperazone sodium for injection, and amoxicillin sodium and clavulanate potassium for injection; cefuroxime sodium, ceftazidime, cefotaxime sodium, and ceftriaxone sodium for injections; and ampicillin capsules. In addition, the company offers medical protective and disposable surgical masks, medical disposable protective gowns, and isolation gowns. It offers its products under the Hongyan Yaopin, Guangwei, Renmin Tongtai, Hayao Shengwu, Baohulu, Manshanhong, Hutong, Hayaoliu, Gaizhonggai, Sanchine, Shiyitang, and Hayao brands. The company is based in Harbin, China.